SLC5A2 and metabolic dysfunction-associated steatohepatitis: On the other hand, NASH was significantly reduced in pathological grade in the PHZ-treated STAM mice compared to that in non-treated STAM mice (Fig. 2b, c, Supplementary Fig. 2c–f), as was observed in previous studies18,19 in which SGLT2 inhibitors were used.